cimerli

Generic: ranibizumab-eqrn

Labeler: sandoz inc
NDC Directory HUMAN PRESCRIPTION DRUG BLA Inactive Finished

Drug Facts

Product Profile

Brand Name cimerli
Generic Name ranibizumab-eqrn
Labeler sandoz inc
Dosage Form INJECTION, SOLUTION
Routes
INTRAVITREAL
Active Ingredients

ranibizumab .5 mg/.05mL

Manufacturer
Sandoz Inc

Identifiers & Regulatory

Product NDC 61314-625
Product ID 61314-625_0bfab18c-289a-42a1-b426-0fc2274a7a3e
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category BLA
Application Number BLA761165
Listing Expiration 2026-12-31
Marketing Start 2024-12-12

Pharmacologic Class

Established (EPC)
vascular endothelial growth factor inhibitor [epc]
Mechanism of Action
vascular endothelial growth factor inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 61314625
Hyphenated Format 61314-625

Supplemental Identifiers

RxCUI
2612675 2612681 2612684 2612687
UNII
ZL1R02VT79
NUI
N0000193542 N0000193543

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name cimerli (source: ndc)
Generic Name ranibizumab-eqrn (source: ndc)
Application Number BLA761165 (source: ndc)
Routes
INTRAVITREAL
source: ndc

Resolved Composition

Strengths
  • .5 mg/.05mL
source: ndc
Packaging
  • 1 VIAL, SINGLE-DOSE in 1 CARTON (61314-625-94) / .05 mL in 1 VIAL, SINGLE-DOSE
source: ndc

Packages (1)

61314-625-94 1 VIAL, SINGLE-DOSE in 1 CARTON (61314-625-94) / .05 mL in 1 VIAL, SINGLE-DOSE

Ingredients (1)

ranibizumab (.5 mg/.05mL)

Linked Drug Pages (1)

CIMERLI ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["INTRAVITREAL"], "spl_id": "0bfab18c-289a-42a1-b426-0fc2274a7a3e", "openfda": {"nui": ["N0000193542", "N0000193543"], "unii": ["ZL1R02VT79"], "rxcui": ["2612675", "2612681", "2612684", "2612687"], "spl_set_id": ["4b383d74-4830-4587-95f7-c32a39268df7"], "pharm_class_epc": ["Vascular Endothelial Growth Factor Inhibitor [EPC]"], "pharm_class_moa": ["Vascular Endothelial Growth Factor Inhibitors [MoA]"], "manufacturer_name": ["Sandoz Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-DOSE in 1 CARTON (61314-625-94)  / .05 mL in 1 VIAL, SINGLE-DOSE", "package_ndc": "61314-625-94", "marketing_start_date": "20241212"}], "brand_name": "CIMERLI", "product_id": "61314-625_0bfab18c-289a-42a1-b426-0fc2274a7a3e", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Vascular Endothelial Growth Factor Inhibitor [EPC]", "Vascular Endothelial Growth Factor Inhibitors [MoA]"], "product_ndc": "61314-625", "generic_name": "ranibizumab-eqrn", "labeler_name": "Sandoz Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "CIMERLI", "active_ingredients": [{"name": "RANIBIZUMAB", "strength": ".5 mg/.05mL"}], "application_number": "BLA761165", "marketing_category": "BLA", "marketing_start_date": "20241212", "listing_expiration_date": "20261231"}